Purpose: Cisplatin (CDDP) and etoposide (VP16) are considered major standard cytotoxic
drugs for small cell lung cancer (SCLC). The present systematic review had as its objective …

Epirubicin is the 4′ epimer of the anthracycline antibiotic doxorubicin, and has been used
alone or in combination with other cytotoxic agents in the treatment of a variety of …

Chemotherapy is the backbone of small-cell lung cancer therapy. However, optimal drug
combinations and schedules remain to be defined and there is hitherto no world-wide …

Background Small cell lung cancer (SCLC) is a very fast growing form of cancer and is
characterised by early metastasis. As a result, chemotherapy is the mainstay of treatment. A …

In 40 patients with neoplastic disorders treated with chemotherapy containing anthracyclines
or 5-fluorouracil, objective changes of the oral mucosa were registered in 22 patients (55%) …

High-dose epirubicin plus cisplatin was compared with the reference regimen of
etoposide/cisplatin in small-cell lung cancer (SCLC). Four hundred two previously untreated …

Objective: To conduct an economic analysis on the use of carboplatin versus cisplatin over
multiple courses in patients with lung [nonsmall cell lung cancer (NSCLC) and small cell …

The purpose of this study was to search for the maximal tolerated dose of cisplatin in the
cisplatin plus high-dose epirubicin combination for patients with non–small-cell lung cancer …

Background: Some studies (but not others) suggested that high doses are beneficial in small
cell lung cancer (SCLC). We hypothesized that dose-response curve (DRC) shape reflects …

Prospective clinical trials on cancer started in Central and Eastern Europe in the early 70s
under the auspices of the Council of Mutual Economic Assistance (CMEA). The objective of …